https://www.selleckchem.com/products/tmp269.html
Antibody testing also posed a specific obstacle given lack of standardization, variable performance of the assays in use and uncertain interpretation of results. In LMICs, an extant transfusion deficit, suboptimal models of donor recruitment (e.g. reliance on replacement and paid donors), limited laboratory capacity for pre-donation qualification and operational considerations could impede wide adoption. Conclusion There has been wide scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By con
Like
Comment
Share
